Chapter 1 of 25
What you will learn
- Identify the endometrium, uterine muscle and cervix.
- Distinguish endometrial carcinoma from other uterine cancers.
- Understand why pathology and molecular tests are needed together.
The uterus and its lining
The uterus, also called the womb, is a muscular organ in the pelvis, between the bladder and rectum. Its inner lining is the endometrium. Before menopause this lining usually grows and sheds in response to changing hormones, producing menstrual bleeding. The thick muscle around it is the myometrium. The cervix is the lower opening into the vagina; it has different cells and a different cancer-prevention pathway.
Cancer develops when changes in cells allow uncontrolled growth. Endometrial cancer usually starts in the glands of the lining. A tumour may remain near the surface, grow into the myometrium, enter small lymphatic or blood vessels, or spread elsewhere. These are possibilities, not an inevitable sequence for every person. The depth of muscle invasion and any spread help determine treatment after surgery.
Similar names, different diseases
| Term | What it means | Why the distinction matters |
|---|---|---|
| Endometrial carcinoma | Cancer arising from the uterine lining | This guide's main subject |
| Cervical cancer | Cancer beginning in the cervix | HPV prevention, staging and treatment differ |
| Uterine sarcoma | Cancer arising in muscle or supporting tissue | Requires a separate specialist pathway |
| Carcinosarcoma | Aggressive carcinoma with carcinoma-like and sarcoma-like components | Staged and generally treated within endometrial carcinoma pathways |
“Uterine cancer” is an umbrella term, so ask for the full diagnosis rather than relying on that phrase. Endometrial cancer is not usually caused by HPV. A normal cervical screening result does not exclude it, and HPV vaccination is not an endometrial cancer vaccine. People who have a uterus can develop this disease regardless of gender identity; care should respect personal language and preferences.
Common and uncommon types
Endometrioid carcinoma is the most common histological type. Histology means the appearance of tissue under a microscope. Many endometrioid cancers are lower grade and found while confined to the uterus, but some are high grade or have spread. Less common types include serous, clear cell, undifferentiated and dedifferentiated carcinoma, and carcinosarcoma. The name alone does not reveal everything about an individual's outlook.
Modern assessment adds molecular classification: POLE-mutated, mismatch repair deficient, p53-abnormal or no specific molecular profile. These describe biological patterns inside the tumour. They can explain why two cancers that look similar behave differently. Molecular results do not replace the assessment of where the cancer is or a discussion of the person's health and priorities.
The first steps after diagnosis
A biopsy establishes the tissue diagnosis. Imaging may then help plan an operation or another treatment. For many people, surgery both removes the cancer and supplies the information needed for final staging. Some need radiotherapy, chemotherapy, immunotherapy or other medicines; many with low-risk disease need no additional treatment after surgery. “Cancer treatment” therefore does not automatically mean chemotherapy.
Keep copies of the biopsy, imaging, operation and molecular reports. Ask who will coordinate results and when the multidisciplinary team will discuss them. A short interval to obtain essential information is different from being lost to follow-up; obtain a named contact if appointments are unclear.
Misconceptions and questions
Is cancer always painful? No. Unusual bleeding may be the first or only symptom. Is it my fault? No. Risk factors describe probabilities and do not assign blame. Can it be cured? Many cancers diagnosed at an early stage are treated with curative intent, but an individual assessment needs the complete results.
Take-home messages
- The lining and muscle of the uterus are different structures.
- Confirm the exact histological and molecular diagnosis.
- Ask which results are still needed before a treatment plan is final.
Related chapters
- Symptoms and Early Warning Signs
- Molecular Classification: The Four Major Groups
- How Doctors Choose Treatment
References and review status
- NCI: Endometrial Cancer Treatment PDQ
- ESGO–ESTRO–ESP endometrial carcinoma guideline update, 2025
- WHO Classification of Female Genital Tumours, fifth edition, 2020
Evidence/editorial check: 30 October 2026. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.
Evidence scope and update policy